Compare Amgen, Inc. (AMGN) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Live Nation Entertainment, Inc. — how do they compare? Amgen, Inc. trades at $358.74 (market cap $196.12B), while Live Nation Entertainment, Inc. trades at $183.25 (market cap $41.84B). The key difference: Amgen, Inc. is far larger — about 4.7× Live Nation Entertainment, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | LYV | |
|---|---|---|
Market Cap | $196.12B | $41.84B |
Sector | Health | Industrials |
52-Week High | $388.16 | $186.59 |
52-Week Low | $271.18 | $125.61 |
Enterprise Value | $241.41B | $43.34B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Live Nation (LYV) trades at $179.79, down 1.53% today, with strong analyst support (88.6% buy ratings) and a $200.20 consensus price target. The stock shows bullish technical signals despite recent earnings misses, with revenue growth to $25.2B in 2025 but net margins narrowing to 1.96%. Recent news highlights strong concert demand and strategic initiatives, though legal challenges and cost pressures remain concerns.
Outlook remains positive based on analyst consensus and projected cash flow growth, but investors face risks from volatile earnings, high debt levels, and regulatory scrutiny. The stock's elevated P/E of 117.5 reflects growth expectations that must materialize to justify current valuations amid competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
